Cost-Effectiveness Analysis of Enoxaparin versus Unfractionated Heparin in Patients with Acute Coronary Syndrome in Poland: Modelling Study from the Hospital Perspective

By Orlewska E.  

PharmacoEconomics, Vol. 21, Iss. 10, 2003-01 ,pp. : 737-748

Adis International

Access to resources Recommend Favorite

A Cost-Effectiveness Analysis of Fondaparinux Sodium Compared with Enoxaparin Sodium as Prophylaxis Against Venous Thromboembolism: Use in Patients Undergoing Major Orthopaedic Surgery

By Sullivan S.D.  

PharmacoEconomics, Vol. 22, Iss. 9, 2004-01 ,pp. : 605-620

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Rivaroxaban versus Enoxaparin for Prevention of Post-Surgical Venous Thromboembolism from a US Payer's Perspective

By Duran Aurea  

PharmacoEconomics, Vol. 30, Iss. 2, 2012-02 ,pp. : 87-101

Adis International

Access to resources Recommend Favorite

An open-label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN

By Schellong Sebastian M   Haas Sylvia   Greinacher Andreas   Schwanebeck Uta   Sieder Christian   Abletshauser Claudia   Bramlage Peter   Riess Hanno  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 18, 2010-12 ,pp. : 2953-2961

Informa Healthcare

Access to resources Recommend Favorite

Cost-Effectiveness Analysis of Enoxaparin versus Unfractionated Heparin for Acute Coronary Syndromes: A Canadian Hospital Perspective

By Balen R.M.  

PharmacoEconomics, Vol. 16, Iss. 5, 1999-11 ,pp. : 533-542

Adis International

Access to resources Recommend Favorite